Tissue-specific cancer stem/progenitor cells: Therapeutic implications

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Translational Cancer Research

Background:

• Standard cancer treatments like surgery, chemotherapy, and radiation often spare cancer stem cells (CSCs), leading to tumor recurrence.
• CSCs are a resistant subpopulation within tumors, contributing to treatment failure and disease relapse.
• Effective cancer therapy requires targeting these CSCs.

Purpose of the Study:

• To review current tissue-specific cancer stem cell (CSC) markers in five common solid tumors.
• To highlight the utility of patient-derived organoids (PDOs) in cancer research.
• To discuss the potential of PDOs for modeling cancer and evaluating CSC-targeting therapies.

Main Methods:

• Literature review of CSC markers in five prevalent solid tumors.
• Discussion of the advantages of three-dimensional patient-derived organoid (PDO) culture models.
• Analysis of PDOs as a platform for pre-clinical cancer modeling.

Main Results:

• Identification and discussion of updated CSC markers across five major solid tumors.
• Emphasis on the relevance of PDOs for creating accurate pre-clinical cancer models.
• Demonstration of PDOs' capability in evaluating CSC-based therapeutic efficacy.

Conclusions:

• Targeting cancer stem cells (CSCs) is essential for overcoming treatment resistance and preventing cancer recurrence.
• Patient-derived organoids (PDOs) represent a significant advancement in pre-clinical cancer modeling.
• PDOs provide a valuable platform for developing personalized anti-cancer therapies and predicting drug responses.